B7-H3 ADC
QLC5508 ADC Phase 1 Results Positive in ES-SCLC, Qilu to Commercialize in China
QLC5508 (MHB088C) shows promising Phase 1 efficacy and manageable safety in previously treated ES-SCLC patients. Qilu Pharmaceutical secures exclusive rights to develop and commercialize the ADC in Greater China.